Real‐world use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infection
Authors:
Open Access
- 12 January 2017
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 45 (5) , 688-700
Abstract
Summary: Background: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data.Aim: To validate the use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infection under real‐word conditions.Methods: The German Hepatitis C‐Registry is a large national non‐interventional real‐world study for patients with chronic hepatitis C. A total of 1322 GT3 patients were enrolled (211 untreated and 1111 treated patients).Results: Between February 2014 and September 2015, five different treatment strategies have been used (PegIFN+RBV, PegIFN+RBV+SOF, SOF+RBV, DCV+SOF±RBV, LDV/SOF±RBV). Treatment uptake and use of treatment concepts changed markedly and rapidly during the study influenced by new approvals, guideline recommendations, and label updates. PegIFN‐based therapies constantly declined while DCV‐based therapies increased with one interruption after the approval of LDV/SOF, which was frequently used until new guidelines recommended not using this combination for GT3. Per‐protocol SVR ranged from 80.9% in the PegIFN+RBV group to 96.1% in PegIFN+RBV+SOF treated patients. Treatment‐experienced patients with cirrhosis showed a suboptimal SVR of 68% for SOF+RBV but a high SVR of 90–95% for DCV+SOF±RBV. The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV containing regimens.Conclusions: Real‐world data can validate the effectiveness and safety for treatment regimens that had previously been approved with limited data, in particular for specific subgroups of patients. The present study demonstrates how rapid new scientific data, new treatment guidelines, new drug approvals and label changes are implemented into routine clinical practice today.Keywords
Funding Information
- Deutsches Zentrum für Infektionsforschung
This publication has 27 references indexed in Scilit:
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2015
- Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisHepatology, 2014
- Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAAPLOS ONE, 2014
- Is genotype 3 of the hepatitis C virus the new villain?Hepatology, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3New England Journal of Medicine, 2014
- Review article: HCV genotype 3 – the new treatment challengeAlimentary Pharmacology & Therapeutics, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Epidemiologie der chronischen Hepatitis C in Deutschland - Eine Analyse von 10 326 Hepatitis-C-Virus-Infizierten aus Schwerpunktpraxen und -ambulanzenZeitschrift für Gastroenterologie, 2008